4.7 Article

Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication

期刊

SCIENTIFIC REPORTS
卷 12, 期 1, 页码 -

出版社

NATURE PORTFOLIO
DOI: 10.1038/s41598-022-05492-5

关键词

-

资金

  1. Ministry of Education, Culture, Sports, Science, and Technology of Japan
  2. Japan Society for the Promotion of Science
  3. Japan Agency for Medical Research and Development
  4. Ministry of Health, Labour, and Welfare of Japan [20fk0210072h0001, 20fk0210058h0002, 20fk0210048h0002]
  5. Gilead Sciences Inc.
  6. Bristol Myers Squibb

向作者/读者索取更多资源

Liver stiffness measurement is a useful tool in assessing liver fibrosis. This study identifies age and liver stiffness as important risk factors for hepatocellular carcinoma (HCC) following hepatitis C (HCV) eradication. Low-risk individuals have a lower incidence of HCC.
Liver stiffness measurement (LSM) is a useful tool for assessing advanced liver fibrosis, an important risk factor for hepatocellular carcinoma (HCC) following hepatitis C (HCV) eradication. This study aimed to clarify the non-invasive factors associated with HCC following sustained virological response (SVR) and to identify the low-risk group. 567 patients without history of HCC who achieved SVR at 24 weeks (SVR24) after IFN-free treatment were retrospectively analyzed. The cumulative incidence of HCC and the risk factors were examined using pre-treatment and SVR24 data. The median observation period was 50.2 months. Thirty cases of HCC were observed, and the 4-year cumulative incidence of HCC was 5.9%. In multivariate analysis, significant pre-treatment factors were age >= 71 years (hazard ratio [HR]: 3.402) and LSM >= 9.2 kPa (HR: 6.328); SVR24 factors were age >= 71 years (HR: 2.689) and LSM >= 8.4 kPa (HR: 6.642). In cases with age < 71 years and LSM < 8.4 kPa at the time of SVR24, the 4-year cumulative incidence of HCC was as low as 1.1%. Both pre-treatment LSM (>= 9.2 kPa) and SVR24 LSM (>= 8.4 kPa) and age (>= 71 years) are useful in predicting the risk of HCC after SVR with IFN-free treatment. Identification of low-risk individuals may improve the efficiency of follow-up.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据